Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Systemic adverse events following rituximab therapy in patients with Graves' disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Manifesto for the current understanding and management of traumatic brain injury-induced hypopituitarism

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Rapid changes in plasma androgens during insulin withdrawal in male type 1 (insulin-dependent) diabetics

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Rituximab (RTX) therapy has shown promising results in Graves' disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events in GD patients treated with RTX.
Original languageEnglish
JournalJournal of Endocrinological Investigation
Volume34
Issue number7
Pages (from-to)e163-7
ISSN0391-4097
DOIs
Publication statusPublished - 2011

ID: 32712566